Results 191 to 200 of about 64,892 (357)

Efficacy of Anti-D Immunoglobulin (Anti-D) and Intravenous Immunoglobulin(IVIg) in the Treatment of Acute Immune Thrombocytopenic Purpura (ITP) in Children. † 665 [PDF]

, 1997
Reneé M. Madden, Salvatore Bertolone, Ronald M. Kline, Chandrakant C. Patel, Cynthia E. Gonzales, D.Lucille Fennewald, Michael D. Tarantino   +6 more
openalex   +1 more source

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

Advanced NanoBiomed Research, EarlyView.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari, Yunhui Min, Eun‐Ju Ko, Doyoung Kwon, Rehan Khan, Young‐Ok Son   +5 more
wiley   +1 more source

Are Intravenous Immunoglobulins Effective in Preventing Primary EBV Infection in Pediatric Kidney Transplant Recipients? [PDF]

Medicina (Kaunas)
Bertazza Partigiani N, Bertozzi V, Sangermano M, Benetti E.   +3 more
europepmc   +1 more source

Improvement in Primary Autoimmune Myelofibrosis Following a Short Course of Steroids and Intravenous Immunoglobulins. [PDF]

Cureus, 2022
Prakash S, Alhariri S, Hassan M, Patel PK, Corral J.   +4 more
europepmc   +1 more source

Use of Intravenous Immunoglobulin in Critically Ill Patients [PDF]

, 2014
Summer Donovan, Gonzalo Bearman
openalex   +1 more source

Improvement of plaquelike cutaneous mucinosis after intravenous immunoglobulins treatment

JAAD Case Reports, 2020
Jorge Magdaleno-Tapial, MD, Cristian Valenzuela-Oñate, MD, Álvaro Martínez-Doménech, MD, Marta García-Legaz-Martínez, MD, Juan José Tamarit-García, PhD, Violeta Zaragoza-Ninet, PhD, Víctor Alegre-de Miquel, PhD, Amparo Pérez-Ferriols, PhD   +7 more
doaj   +1 more source

Sequential treatment of progressive multifocal leukoencephalopathy with intravenous immunoglobulins and pembrolizumab. [PDF]

J Neurovirol, 2022
Boesl F, Allers K, Herm J, Scheider T, Franke C.   +4 more
europepmc   +1 more source

Intravenous immunoglobulin in dermatology

Indian Journal of Dermatology, 2009
openaire   +3 more sources

Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab

Arthritis &Rheumatology, EarlyView.
Objective The objective of the study was to determine risk factors for relapse of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) after reinduction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post hoc analysis of the RITAZAREM clinical trial.
Ellen Romich, Joshua F. Baker, Thomas R. Riley IV, Ian Green, Rennie L. Rhee, Carol A. McAlear, Ulrich Specks, Rona M. Smith, David R. Jayne, Peter A. Merkel, for the RITAZAREM Investigators, Reem Al‐jayyousi, Yoshihiro Arimura, Jacqueline Andrews, Simon Bond, Marianna Nodale, Annette Bruchfeld, Brian Camilleri, Simon Carette, Chee Kay Cheung, Michael Clarkson, Janak de Zoysa, Vimal Derebail, Tim Doulton, Tomomi Endo, Eri Muso, Tatsuo Tsukamoto, Alastair Ferraro, Lindsy Forbess, Shouichi Fujimoto, Shunsuke Furuta, Ora Gewurz‐Singer, Yoshitomo Hamano, Lorraine Harper, Toshiko Ito‐Ihara, Rachel B. Jones, Nader Khalidi, Rainer Klocke, Curry L. Koening, Yoshinori Komagata, Hajime Kono, Shunya Uchida, Carol A. Langford, Peter Lanyon, Sarah Lawman, Raashid Luqmani, Larry W. Moreland, Kim Mynard, Patrick Nachman, Christian Pagnoux, Chen Au Peh, Charles Pusey, Dwarakanathan Ranganathan, Ken‐ei Sada, Richard Smith, Richard Watts, Robert Spiera, Antoine G. Sreih, Kazuo Suzuki, Vladamir Tesar, Augusto Vaglio, Giles Walters, Caroline Wroe   +62 more
wiley   +1 more source

Osmotic Nephropathy Induced by L-Proline Stabilized Sucrose-free Intravenous Immunoglobulins: A Case Report. [PDF]

Kidney Med
Ulpiano Trillig A, Rotman S, Mehier P, Rossier A, Vogel G.   +4 more
europepmc   +1 more source